Compare Hasbro, Inc. (HAS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Hasbro, Inc. trades at $89.02 (market cap $11.53B), while State Street SPDR S&P Biotech ETF trades at $153.37. The key difference: Hasbro, Inc. pays a 3.44% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Hasbro, Inc. nearer its low. Which is the better fit depends on your goals.
| HAS | XBI | |
|---|---|---|
Market Cap | $11.53B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $105.88 | $164.28 |
52-Week Low | $70.95 | $85.16 |
Enterprise Value | $13.80B | — |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $81.56, showing minimal daily movement with a 0.01% gain. The stock exhibits a bearish technical signal, with RSI indicating overbought conditions near-term. Fundamentally, the company reported a net loss of -$322.4M in 2025 despite revenue growth to $4.7B, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights upcoming Q2 2026 earnings and new product launches like Blooms by Play-Doh targeting adult consumers.
The outlook remains mixed with analyst consensus leaning bullish (51.5% buy ratings) and a $104.75 price target suggesting 28% upside. Key risks include persistent negative profit margins, high debt levels, and competitive pressures in the toy industry. Earnings performance on July 21 will be critical for near-term direction.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
